CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.
Now available, CCTG clinical trial Infographics en français!
A great resource for clinical staff and investigators to help patients or even students gain a basic understanding of some of the more complex details of clinical trial research. If you have any questions or would like your site logo added to any of our infographics please contact Lisa Callahan.
You can access our CCTG Infographics in both Francais and English here.
The book “Clinical Trials” by Daniel Schwartz, Robert Flamant and Joseph Lellouch, which described in full detail their distinction between pragmatic and explanatory clinical trials, was published in English in 1980, the year I became the NCIC CTG (now CCTG) director. Their ideas strongly influenced me and my colleagues thinking about how our trials should be designed and conducted.
Breast International Group (BIG) has announced that the second interim analysis of OlympiA trial building on the earlier published results (NEJM) will lead to fewer deaths among patients with germline BRCA-mutated (gBRCA) breast cancer, as the U.S. Food and Drug Administration announced last Friday approval of olaparib for gBRCA breast cancer patients who have had chemotherapy.